From Self-sufficiency
Jump to: navigation, search
Chemical structure of (R)-DOI
ball-and-stick model of (R)-DOI
style="background: #F8EABA; text-align: center;" colspan="2" | Identifiers
CAS number 64584-34-5, (R): 82864-06-0
(S): 99665-04-0
HCl: 82864-02-6
SMILES Script error: No such module "collapsible list".
style="background: #F8EABA; text-align: center;" colspan="2" | Properties
Molecular formula C11H16INO2
Molar mass 321.15 g/mol
Melting point

201 °C (hydrochloride)

Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa)
Infobox references

2,5-dimethoxy-4-iodoamphetamine (DOI) is a psychedelic drug and a substituted amphetamine of the phenethylamine family. Despite being a substituted amphetamine, it is not a stimulant. DOI has a stereocenter and R-(-)-DOI is the more active stereoisomer. In neuroscience research, [125I]-R-(-)-DOI is used as a radioligand and indicator of the presence of 5-HT2A serotonin receptors. When ingested recreationally, DOI is active at a dosage of 1.5 - 3.0mg (orally) and has a duration of 16 - 30 hours (approximately twice as long as LSD). DOI's effects have been compared to LSD, although there are differences that experienced users can distinguish. Besides the longer duration, the trip tends to be more energetic than an LSD trip, with more body load and a different subjective visual experience. The after effects include residual stimulation and difficulty sleeping, which, depending on the dose, may persist for days.[1] It is often sold as a substitute for LSD, or even sold falsely as LSD[2], which may be dangerous because DOI does not have the same established safety profile as LSD. Unlike LSD, the psychedelic amphetamines (including DOI) can have harmful and potentially fatal physical effects in overdose. Although there have been no known deaths due to DOI ingestion, it is relatively new on the recreational scene so long-term effects are not known.


DOI is a selective 5-HT2A, 5-HT2B, and 5-HT2C receptor partial agonist. Its psychedelic effects are mediated by its agonistic properties at the 5-HT2A receptor. Due to its selectivity, DOI is often used in scientific research when studying the 5-HT2 receptor subfamily.

The solubility of DOI hydrochloride in H2O is 10 mg/ml, and in ethanol 2 mg/ml.[3]

DOI has also recently been shown to be an extremely potent inhibitor of Tumor necrosis factor-alpha, an inflammatory mediator which is an important target for current research into degenerative conditions such as arthritis and Alzheimer's disease, where the disease process involves tissue damage through chronic inflammation. This could make DOI and other 5-HT2A agonists an entirely new area for development of novel treatments for these conditions.[4]


DOI was first synthesized by Alexander Shulgin. The radioactive iodine-125 form of DOI was first developed in the lab of David E. Nichols. In January 2007, British Police reported that 3 young men had taken ill, reportedly, after taking DOI at a rave in Biggleswade, near Milton Keynes, and warned others who had taken it to seek medical attention. This would appear to be the first indication that DOI has found more widespread use as a recreational drug in the UK. [5] The fact that it was published in Shulgin's PiHKAL and that it is a substituted phenethylamine suggest that it is a Class A drug in the UK.

An extremely large increase of the hallucinogenic drug has been seen in sales in Adelaide, Australia. It is commonly sold as LSD or just "trips".

See also


Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

External links


ru:2,5-диметокси-4-иодамфетамин sr:2,5-dimetoksi-4-jodoamfetamin

  1. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  2. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  3. "D101 DOI hydrochloride ≥98% (HPLC), solid". 
  4. Yu, B.; Becnel, J.; Zerfaoui, M.; Rohatgi, R.; Boulares, A. H.; Nichols, C. D. (2008). "Serotonin 5-Hydroxytryptamine2A Receptor Activation Suppresses Tumor Necrosis Factor-α-Induced Inflammation with Extraordinary Potency". Journal of Pharmacology and Experimental Therapeutics. 327 (2): 316–323. doi:10.1124/jpet.108.143461. PMID 18708586. .
  5. BBC, "New drug alert as three taken ill", BBC News, 29 January 2007.